This is a major de-risking and revenue catalyst for Telix, establishing a new commercial product in a large unmet-need market. Traders should expect significant upside on the open; watch for initial sales ramp commentary and potential analyst upgrades. The Phase 3 brain metastases expansion study adds further pipeline optionality.
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $11.78entry
- T+1 · 2mo ago +8.91%α +9.37% · $12.83
- T+5 · 8w ago −3.99%α −4.10% · $11.31
- T+20 · 5w ago −4.16%α −6.42% · $11.29
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix Pharmaceuticals announced FDA approval of Pixclara® (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma (brain cancer), for differentiating recurrent or progressive glioma from treatment-related change in adults and pediatric patients. This approval addresses a significant unmet need in a market with ~24,000 new U.S. glioma cases annually and reinforces Telix's leadership in theranostics, expanding its commercial precision diagnostics portfolio alongside Illuccix and Gozellix. The approval is a transformative catalyst for Telix, particularly as an early-stage biotech with a first-in-class commercial asset in a new indication, likely driving substantial stock appreciation.
Key Facts
- FDA approved Pixclara (floretyrosine F 18) for PET imaging to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients 1 month+
- Pixclara is the first FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer)
- Approximately 24,000 new glioma cases are diagnosed in the U.S. each year
- FET-PET imaging is recommended in international clinical practice guidelines including NCCN Guidelines
- Pixclara is also in a Phase 3 registrational study for potential indication expansion for brain metastases
- Telix is a commercial-stage radiopharmaceutical company with a precision diagnostics portfolio including Illuccix and Gozellix
Financial Impact
First FDA-approved FET-PET imaging drug for glioma in a ~24,000 annual U.S. case market; transformative for Telix's commercial diagnostics business
Risk Factors
- Competition from off-label use of non-FDA-approved FET-PET agents or alternative imaging modalities
- Reimbursement and market access challenges for a new diagnostic agent
- Potential for slower-than-expected physician adoption despite guideline recommendations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360898 |
Track record
27 reports on TLX
9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Viewing Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers